Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.25
NAS:AKRX's Cash-to-Debt is ranked lower than
84% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NAS:AKRX: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.37 Max: No Debt
Current: 0.25
Equity-to-Asset 0.42
NAS:AKRX's Equity-to-Asset is ranked lower than
78% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:AKRX: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AKRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.55 Max: 0.93
Current: 0.42
0.18
0.93
Interest Coverage 7.67
NAS:AKRX's Interest Coverage is ranked lower than
77% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. NAS:AKRX: 7.67 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 2.71  Med: 7.62 Max: No Debt
Current: 7.67
Piotroski F-Score: 6
Altman Z-Score: 3.19
Beneish M-Score: -1.64
WACC vs ROIC
10.61%
15.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 29.33
NAS:AKRX's Operating Margin % is ranked higher than
92% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. NAS:AKRX: 29.33 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AKRX' s Operating Margin % Range Over the Past 10 Years
Min: -37.46  Med: 20.31 Max: 29.91
Current: 29.33
-37.46
29.91
Net Margin % 16.50
NAS:AKRX's Net Margin % is ranked higher than
81% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NAS:AKRX: 16.50 )
Ranked among companies with meaningful Net Margin % only.
NAS:AKRX' s Net Margin % Range Over the Past 10 Years
Min: -36.24  Med: 14.56 Max: 31.41
Current: 16.5
-36.24
31.41
ROE % 24.93
NAS:AKRX's ROE % is ranked higher than
88% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:AKRX: 24.93 )
Ranked among companies with meaningful ROE % only.
NAS:AKRX' s ROE % Range Over the Past 10 Years
Min: -50.57  Med: 21.2 Max: 35.12
Current: 24.93
-50.57
35.12
ROA % 9.45
NAS:AKRX's ROA % is ranked higher than
76% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NAS:AKRX: 9.45 )
Ranked among companies with meaningful ROA % only.
NAS:AKRX' s ROA % Range Over the Past 10 Years
Min: -33.5  Med: 8.41 Max: 24.27
Current: 9.45
-33.5
24.27
ROC (Joel Greenblatt) % 69.84
NAS:AKRX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. NAS:AKRX: 69.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -41.62  Med: 56.56 Max: 74.27
Current: 69.84
-41.62
74.27
3-Year Revenue Growth Rate 47.10
NAS:AKRX's 3-Year Revenue Growth Rate is ranked higher than
95% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NAS:AKRX: 47.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AKRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 10.6 Max: 60.1
Current: 47.1
-37.1
60.1
3-Year EBITDA Growth Rate 52.50
NAS:AKRX's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. NAS:AKRX: 52.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AKRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.8 Max: 128.9
Current: 52.5
0
128.9
3-Year EPS without NRI Growth Rate 47.30
NAS:AKRX's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NAS:AKRX: 47.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AKRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: 18.6 Max: 93.1
Current: 47.3
-50.4
93.1
GuruFocus has detected 4 Warning Signs with Akorn Inc $NAS:AKRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKRX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AKRX Guru Trades in Q2 2016

George Soros 38,400 sh (New)
Steven Cohen 120,600 sh (New)
Paul Tudor Jones 30,765 sh (New)
Joel Greenblatt 403,835 sh (New)
Jim Simons 175,600 sh (New)
Andreas Halvorsen Sold Out
Columbia Wanger 2,076,628 sh (-0.96%)
John Paulson 9,012,900 sh (-3.28%)
Mario Gabelli 44,600 sh (-3.67%)
Murray Stahl 15,028 sh (-44.73%)
» More
Q3 2016

AKRX Guru Trades in Q3 2016

Lee Ainslie 116,040 sh (New)
Richard Snow 149,070 sh (New)
Paul Tudor Jones 31,282 sh (+1.68%)
Mario Gabelli 44,600 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Steven Cohen Sold Out
John Paulson 8,974,400 sh (-0.43%)
Murray Stahl 14,766 sh (-1.74%)
Joel Greenblatt 227,948 sh (-43.55%)
Columbia Wanger 1,064,814 sh (-48.72%)
» More
Q4 2016

AKRX Guru Trades in Q4 2016

First Pacific Advisors 136,990 sh (New)
David Dreman 18,498 sh (New)
Steven Cohen 315,200 sh (New)
Richard Snow 376,150 sh (+152.33%)
Murray Stahl 19,927 sh (+34.95%)
Lee Ainslie 151,370 sh (+30.45%)
Mario Gabelli 56,900 sh (+27.58%)
Paul Tudor Jones 37,381 sh (+19.50%)
Columbia Wanger 1,179,455 sh (+10.77%)
John Paulson 8,686,500 sh (-3.21%)
Joel Greenblatt 145,407 sh (-36.21%)
» More
Q1 2017

AKRX Guru Trades in Q1 2017

FPA Capital Fund 380,120 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:SHPHF, NAS:OPK, NAS:MDCO, NYSE:MNK, NYSE:PTHN, NYSE:CTLT, NYSE:TARO, NYSE:VRX, OTCPK:IZQVF, OTCPK:HKMPF, NAS:HZNP, NAS:IRWD, OTCPK:HYPMY, NAS:ENDP, OTCPK:SWPIF, NAS:PCRX, NAS:RDUS, NAS:SUPN, NYSE:RDY, OTCPK:EVTCY » details
Traded in other countries:FDA.Germany,
Headquarter Location:USA
Akorn Inc is a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals.

Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.

Top Ranked Articles about Akorn Inc

FPA Capital Buys Vista Outdoor, Akorn The fund's largest 1st-quarter buys
The FPA Capital Fund (Trades, Portfolio), a Los Angeles-based institutional money management fund, employs a disciplined approach to value investing that seeks superior long-term returns while maintaining a focus on capital preservation. During the first quarter, the fund bought shares of the following stocks: Read more...
FPA Capital Invests in Akorn Company is expanding its operations
FPA Capital Fund (Trades, Portfolio) seeks long-term growth through the careful selection of common stocks and select fixed-income securities. During the first quarter it purchased 380,120 shares in Akorn Inc. (NASDAQ:AKRX) Read more...
Akorn Confirms Discussions with Fresenius Kabi
Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP

LAKE FOREST, Ill., March 02, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ:AKRX), a leading specialty generics pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Ephedrine Sulfate Injection, USP 50 mg/mL in 1 mL single dose ampule.  Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
About Akorn
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.
Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
[email protected]

Read more...
Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP

LAKE FOREST, Ill., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Injection, USP, 500 mg/vial.  This approval is the first new product approval received out of Akorn’s Decatur, Illinois manufacturing facility since the FDA re-inspection in December 2016.
According to IMS Health, sales of Mycophenolate Mofetil for Injection were approximately $43 million for the twelve months ended December 31, 2016. About Akorn
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.
Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.47
AKRX's PE Ratio is ranked higher than
79% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. AKRX: 22.47 )
Ranked among companies with meaningful PE Ratio only.
AKRX' s PE Ratio Range Over the Past 10 Years
Min: 12.14  Med: 34.02 Max: 495
Current: 22.47
12.14
495
Forward PE Ratio 20.88
AKRX's Forward PE Ratio is ranked higher than
61% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. AKRX: 20.88 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.47
AKRX's PE Ratio without NRI is ranked higher than
78% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. AKRX: 22.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
AKRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.14  Med: 34.02 Max: 495
Current: 22.47
12.14
495
Price-to-Owner-Earnings 59.03
AKRX's Price-to-Owner-Earnings is ranked lower than
63% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. AKRX: 59.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AKRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.17  Med: 53.11 Max: 318.4
Current: 59.03
11.17
318.4
PB Ratio 5.04
AKRX's PB Ratio is ranked lower than
61% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. AKRX: 5.04 )
Ranked among companies with meaningful PB Ratio only.
AKRX' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.42 Max: 15.55
Current: 5.04
1.42
15.55
PS Ratio 3.74
AKRX's PS Ratio is ranked higher than
53% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. AKRX: 3.74 )
Ranked among companies with meaningful PS Ratio only.
AKRX' s PS Ratio Range Over the Past 10 Years
Min: 0.75  Med: 6.13 Max: 12.93
Current: 3.74
0.75
12.93
Price-to-Free-Cash-Flow 47.08
AKRX's Price-to-Free-Cash-Flow is ranked lower than
62% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. AKRX: 47.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.51  Med: 84.41 Max: 2950
Current: 47.08
10.51
2950
Price-to-Operating-Cash-Flow 24.97
AKRX's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. AKRX: 24.97 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.08  Med: 44.22 Max: 202.29
Current: 24.97
9.08
202.29
EV-to-EBIT 11.04
AKRX's EV-to-EBIT is ranked higher than
82% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. AKRX: 11.04 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -186.6  Med: 16.55 Max: 330
Current: 11.04
-186.6
330
EV-to-EBITDA 8.72
AKRX's EV-to-EBITDA is ranked higher than
85% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. AKRX: 8.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -498.5  Med: 16.75 Max: 176.3
Current: 8.72
-498.5
176.3
PEG Ratio 0.44
AKRX's PEG Ratio is ranked higher than
94% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. AKRX: 0.44 )
Ranked among companies with meaningful PEG Ratio only.
AKRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.25  Med: 0.4 Max: 1.23
Current: 0.44
0.25
1.23
Shiller PE Ratio 89.42
AKRX's Shiller PE Ratio is ranked lower than
65% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. AKRX: 89.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
AKRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 50.27  Med: 130.54 Max: 2690.5
Current: 89.42
50.27
2690.5
Current Ratio 3.91
AKRX's Current Ratio is ranked higher than
67% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. AKRX: 3.91 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 2.56 Max: 12.3
Current: 3.91
0.3
12.3
Quick Ratio 2.91
AKRX's Quick Ratio is ranked higher than
66% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. AKRX: 2.91 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 1.92 Max: 9
Current: 2.91
0.06
9
Days Inventory 151.52
AKRX's Days Inventory is ranked lower than
67% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. AKRX: 151.52 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 115.68  Med: 148.51 Max: 188.37
Current: 151.52
115.68
188.37
Days Sales Outstanding 92.54
AKRX's Days Sales Outstanding is ranked lower than
61% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. AKRX: 92.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.46  Med: 61.64 Max: 135.84
Current: 92.54
25.46
135.84
Days Payable 49.10
AKRX's Days Payable is ranked lower than
68% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. AKRX: 49.10 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 51.8 Max: 123.76
Current: 49.1
19.92
123.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
AKRX's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. AKRX: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.1  Med: -4.3 Max: 2.3
Current: -8.8
-63.1
2.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.51
AKRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
62% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. AKRX: 2.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AKRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.65  Med: 8.79 Max: 40.47
Current: 2.51
1.65
40.47
Price-to-Median-PS-Value 0.61
AKRX's Price-to-Median-PS-Value is ranked higher than
94% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. AKRX: 0.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.3 Max: 1.97
Current: 0.61
0.08
1.97
Price-to-Peter-Lynch-Fair-Value 0.90
AKRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
86% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. AKRX: 0.90 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AKRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 0.9 Max: 1.77
Current: 0.9
0.54
1.77
Earnings Yield (Greenblatt) % 9.05
AKRX's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. AKRX: 9.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 4.2 Max: 11.1
Current: 9.05
0.3
11.1
Forward Rate of Return (Yacktman) % 52.32
AKRX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. AKRX: 52.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AKRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.5  Med: -0.85 Max: 62.1
Current: 52.32
-15.5
62.1

More Statistics

Revenue (TTM) (Mil) $1,117
EPS (TTM) $ 1.48
Beta1.79
Short Percentage of Float13.75%
52-Week Range $17.61 - 35.40
Shares Outstanding (Mil)124.53

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,032 1,073 1,125
EPS ($) 1.60 1.73 1.80
EPS without NRI ($) 1.60 1.73 1.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigate Apr 25 2017 
Harwood Feffer LLP Announces Investigation of Akorn, Inc. Apr 25 2017 
AKORN (AKRX) ALERT: J&W Launches Investigation into the Sale of Akorn; Is $34 a Fair Price? Apr 25 2017 
FPA Capital Fund Buys 2 Low in Fourth Quarter Apr 11 2017 
FPA Capital Invests in Akorn Apr 11 2017 
Akorn Confirms Discussions with Fresenius Kabi Apr 07 2017 
Valeant: It's Not a Game of Chess Part I Mar 16 2017 
Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP Mar 02 2017 
Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP Feb 28 2017 
John Paulson's Bargain Stock Jan 30 2017 

More From Other Websites
Fresenius US Finance II, Inc. -- Moody's affirms Fresenius SE's Baa3 issuer rating, outlook stable Apr 26 2017
Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up Apr 25 2017
AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... Apr 25 2017
[$$] Fresenius Makes Two Acquisitions to Boost Kabi Clinical Unit Apr 25 2017
Harwood Feffer LLP Announces Investigation of Akorn, Inc. Apr 25 2017
AKORN, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale to Fresenius... Apr 25 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Akorn,... Apr 25 2017
Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More Apr 25 2017
Fresenius Spends Billions On a Falling Akorn Apr 25 2017
AKORN (AKRX) ALERT: J&W Launches Investigation into the Sale of Akorn; Is $34 a Fair Price? Apr 25 2017
Fresenius and Merck Stocks Top DAX on Biosimilars Deal Apr 25 2017
Fresenius picks up M&A pace with Akorn, Merck KGaA deals Apr 25 2017
Germany's Fresenius Kabi to buy Akorn for $4.3 billion Apr 24 2017
Fresenius Buys Akorn for $4.3 Billion in U.S. Expansion Apr 24 2017
Fresenius Kabi to Acquire Akorn Apr 24 2017
Exclusive: Fresenius nears deal to acquire Akorn - sources Apr 24 2017
4 Stocks With Strong Technical Momentum Apr 21 2017
Analyst: Akorn Could Be Sold For As Much As $34 Per Share, But There's Double-Digits Downside If... Apr 11 2017
Akorn Acquisition Talks Send Generic Drugmakers Into Orbit Apr 10 2017
Here's Why Akorn Inc. Rose as Much as 12.8% Today Apr 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)